• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Alpha Tau Medical Ltd.

    3/12/25 4:41:16 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email
    S-8 1 ea0233726-s8_alphatau.htm REGISTRATION STATEMENT

     

    As filed with the Securities and Exchange Commission on March 12, 2025 

    Registration No. 333-          

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

    ALPHA TAU MEDICAL LTD. 

    (Exact name of Registrant as specified in its charter)

     

    State of Israel   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    Kiryat HaMada St. 5

    Jerusalem, Israel

      9777605
    (Address of Principal Executive Offices)   (Zip Code)

     

    Alpha Tau Medical Ltd. 2021 Share Incentive Plan

    Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan 

    (Full Title of the Plan)

     

    Alpha Tau Medical, Inc.

    1 Union Street 3rd Floor 

    Lawrence, MA 01840

    (833) 455-3278 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Michael J. Rosenberg

    Joshua G. Kiernan

    Latham & Watkins LLP

    1271 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 906-1200

     

    Shachar Hadar

    Matthew Rudolph

    Meitar | Law Offices

    16 Abba Hillel Silver Rd.

    Ramat Gan 52506, Israel

    Tel: (+972) (3) 610-3100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☐
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Alpha Tau Medical Ltd. (the “Registrant,” “we” or “our”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register (i) 2,815,223 additional ordinary shares, no par value (“Ordinary Shares”), of the Registrant reserved for issuance under the Alpha Tau Medical Ltd. 2021 Share Incentive Plan (the “2021 Plan”) resulting from an automatic annual increase as of January 1, 2025 and (ii) 703,806 additional Ordinary Shares reserved for issuance under the Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan (the “ESPP”) resulting from an automatic annual increase as of January 1, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the SEC on April 7, 2022 (File No. 333-264169), March 9, 2023 (File No. 333-270406) and March 7, 2024 (File No. 333-277733).

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents filed or to be filed with the SEC:

     

    (a)The Registrant’s Annual Report on Form 20-F, filed by the Registrant with the SEC on March 12, 2025; and

     

    (b)The description of the Registrant’s Ordinary Shares contained in Exhibit 2.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 12, 2025 (File No. 001-41316), including any amendments or reports filed for the purpose of updating such description.

     

    All documents, reports and definitive proxy or information statements filed pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act and certain Reports on Form 6-K furnished by the Registrant to the SEC (which indicate that they are incorporated herein by reference) after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    II-1

     

     

    Item 8. Exhibits.

     

            Incorporation by Reference
    Exhibit No.   Description   Form   File No.   Exhibit No.   Filing Date   Filed / Furnished
    3.1   Amended and Restated Articles of Association of Alpha Tau Medical Ltd.   20-F   001-41316   1.1   March 9, 2023    
    3.2   Specimen Ordinary Share Certificate   F-4   333-258915   4.5   January 5, 2022    
    5.1   Opinion of Meitar | Law Offices.                   *
    23.1   Consent of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, independent registered accounting firm                   *
    23.2   Consent of Meitar | Law Offices (included in Exhibit 5.1).                   *
    24.1   Power of Attorney (included on the signature page of the Registration Statement).                   *
    99.1   2016 Share Incentive Plan of Alpha Tau Medical Ltd.   F-4   333-258915   10.7   August 18, 2021    
    99.2   2021 Share Incentive Plan of Alpha Tau Medical Ltd.   F-4   333-258915   10.8   December 1, 2021    
    99.3   2021 Employee Share Purchase Plan of Alpha Tau Medical   F-4   333-258915   10.9   December 1, 2021    
    107   Filing Fee Table                   *

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Jerusalem, Israel, as of March 12, 2025.

     

      ALPHA TAU MEDICAL LTD.
         
      By: /s/ Uzi Sofer
        Name:  Uzi Sofer
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Uzi Sofer and Raphi Levy, and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             
    /s/ Uzi Sofer   Chief Executive Officer & Chairperson   March 12, 2025
    Uzi Sofer   (Principal Executive Officer)    
             
    /s/ Raphi Levy   Chief Financial Officer   March 12, 2025
    Raphi Levy   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Ruth Alon   Director   March 12, 2025
    Ruth Alon        
             
    /s/ Michael Avruch   Director   March 12, 2025
    Michael Avruch        
             
    /s/ S. Morry Blumenfeld, Ph.D.   Director   March 12, 2025
    S. Morry Blumenfeld, Ph.D.        
             
    /s/ Maya Netser   Director   March 12, 2025
    Maya Netser        
             
    /s/ Alan Adler   Director   March 12, 2025
    Alan Adler        
             
    /s/ David Milch   Director   March 12, 2025
    David Milch        

     

    II-3

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Alpha Tau Medical Ltd. has signed this registration statement on March 12, 2025.

     

      ALPHA TAU MEDICAL INC.
       
      By: /s/ Uzi Sofer
      Name:  Uzi Sofer
      Title: President and Director

     

     

    II-4

     

     

    Get the next $DRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alpha Tau to Participate in May Investor Conferences

      JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025. Event:H.C. Wainwright 3rd Annual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2025Time:3:30 – 4:00PM ETLocation:New York, NY Event:Lytham Partners Spring 2025 Investor ConferenceFormat:1x1 MeetingsDate:May 29, 2025Location:Virtual Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representa

      5/6/25 8:30:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

      Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

      JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.   The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Alpha Tau with a new price target

      Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

      12/15/23 8:07:49 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on Alpha Tau with a new price target

      H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

      4/24/23 7:44:43 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Alpha Tau with a new price target

      Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00

      4/14/22 7:17:36 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    SEC Filings

    See more
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      5/6/25 8:32:02 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13D filed by Alpha Tau Medical Ltd.

      SCHEDULE 13D - Alpha Tau Medical Ltd. (0001871321) (Subject)

      5/1/25 1:59:57 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Alpha Tau Medical Ltd.

      6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

      4/28/25 9:20:18 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

      - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

      3/12/25 4:02:00 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

      JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

      12/17/24 9:00:00 AM ET
      $DRTS
      Medical/Dental Instruments
      Health Care
    • Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

      JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure

      9/1/22 4:15:42 PM ET
      $DRTS
      Medical/Dental Instruments
      Health Care